NCT00002952View on ClinicalTrials.gov

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 1997

Primary Completion Date

August 31, 2002

Study Completion Date

November 30, 2002

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

MART-1 antigen

Melan-A peptide loaded PBMCs (sc, q3wk x 3)

BIOLOGICAL

recombinant MAGE-3.1 antigen

BIOLOGICAL

recombinant interleukin-12

rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)

Trial Locations (1)

60637

University of Chicago Cancer Research Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00002952 - Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter